Q32 Bio Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| – | +867.2% | +88.4% | +19.9% | -15.1% | -19.7% | +8.4% | -79.5% | +96.2% | -33.1% | |
| – | +997.9% | +68.4% | +20.3% | -17.6% | -12.6% | -5.1% | -84.2% | +185.1% | -32.8% | |
| – | +352.7% | -25.9% | +40.7% | +304.3% | -50.2% | -68.6% | -24.6% | +204.3% | -38.1% | |
| – | +1,038.1% | +65.6% | +22.2% | -17.1% | -28.3% | +12.3% | -85.4% | +204.3% | -38.1% | |
| – | – | – | -50.0% | +0.0% | +127.3% | +17.1% | -29.0% | -26.5% | – | |
| – | – | – | – | – | – | +127.6% | – | – | – | |
| – | +483.7% | +60.0% | -17.0% | +30.1% | -37.9% | +22.5% | +346.2% | -62.3% | -77.2% | |
| – | +38.9% | +154.1% | -45.1% | +83.1% | -24.0% | +37.1% | -40.3% | +16.7% | -31.1% | |
| – | – | – | – | – | -90.2% | +726.0% | -30.3% | +161.9% | +86.8% | |
| – | +184.0% | +519.8% | -83.4% | +81.1% | -49.9% | -39.3% | +141.7% | -13.8% | -70.6% | |
| – | – | – | – | – | – | +2.0% | +751.3% | -77.9% | -63.7% | |
| – | +1,210.7% | +99.7% | +31.7% | -24.2% | -13.4% | +4.9% | -202.8% | – | +640.3% | |
| – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | -23.7% | +47.5% | +9.0% | +367.7% | +0.0% | +0.0% | -19.0% | +27.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.